High-Dose Chloroquine for Treatment of Chloroquine-Resistant Plasmodium falciparum Malaria

Journal of Infectious Diseases

Volumn 213, Issue 8, 2016, Pages 1315-1321

  Ursing, Johan ^a,b,c   Rombo, Lars ^b,d   Bergqvist, Yngve ^e   Rodrigues, Amabelia ^a   Kofoed, Poul Erik ^a,f  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b KAROLINSKA INSTITUTE   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e DALARNA UNIVERSITY   (Sweden)

^f KOLDING HOSPITAL   (Denmark)

Author keywords

chloroquine; efficacy; pfcrt; Plasmodium falciparum; resistance

Indexed keywords

CHLOROQUINE; ANTIMALARIAL AGENT; CARRIER PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL PROTEIN;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; GENE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PARASITE CLEARANCE; PFCRT GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MALARIA, FALCIPARUM; PARASITE LOAD; PHASE 4 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD;

ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEMBRANE TRANSPORT PROTEINS; PARASITE LOAD; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84965116708     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv590     Document Type: Article

References (30)

1. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland: WHO, 2010.
2. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
3. Ursing J, Kofoed PE, Rodrigues A, Bergqvist Y, Rombo L. Chloroquine is grossly overdosed and overused but well tolerated in Guinea-Bissau. Antimicrob Agents Chemother 2009; 53:180-5.
4. Ursing J, Kofoed PE, Rodrigues A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: A randomized trial. J Infect Dis 2011; 203:109-16.
5. Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Am J Trop Med Hyg 2007; 76:844-8.
6. Ursing J, Eksborg S, Rombo L, et al. Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance. PLoS One 2014; 9:e86801.
7. Kofoed PE, Ursing J, Poulsen A, et al. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans R Soc Trop Med Hyg 2007; 101:231-8.
8. Kofoed PE, Ursing J, Rodrigues A, Rombo L. Paracetamol versus placebo in treatment of non-severe malaria in children in Guinea-Bissau: A randomized controlled trial. Malar J 2011; 10:148.
9. Veiga MI, Ferreira PE, Bjorkman A, Gil JP. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol Cell Probes 2006; 20:100-4.
10. World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva, Switzerland: WHO, 2007.
11. LindegardhN, ForslundM,GreenMD,KanekoA,BergqvistY.Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in capillary blood on sampling paper by liquid chromatography. Chromatographia 2002:5-12.
12. Boyd E. the growth of the surface area of the human body. Minneapolis, MN: Institute of Child Welfare, 1935.
13. Howard N, Durrani N, Sanda S, Beshir K, Hallett R, Rowland M. Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan. Malaria J 2011; 10:171.
14. Pelleau S, Moss EL, Dhingra SK, et al. Adaptive evolution of malaria parasites in French Guiana: reversal of chloroquine resistance by acquisition of a mutation in pfcrt. Proc Natl Acad Sci U S A 2015; 112:11672-7.
15. Djimde A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquineresistant falciparum malaria. N Engl J Med 2001; 344:257-63.
16. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. Falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861-71.
17. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 2009; 325:1680-2.
18. Summers RL, Dave A, Dolstra TJ, et al. Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporter. Proc Natl Acad Sci U S A 2014; 111:E1759-67.
19. Ch'ng JH, Lee YQ, Gun SY, et al. Validation of a chloroquine-induced cell death mechanism for clinical use against malaria. Cell Death Dis 2014; 5:e1305.
20. Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA. Model system to define pharmacokinetic requirements for antimalarial drug efficacy. Sci Transl Med 2013; 5:205ra135.
21. Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B. the single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol 1984; 26:521-30.
22. Ursing J, Schmidt BA, Lebbad M, et al. Chloroquine resistant P. Falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage? Infect Genet Evol 2007; 7:555-61.
23. Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007; 2:e6.
24. Canete R, Rivas DE, Escobedo AA, Gonzalez ME, Almirall P, Brito K. A randomized, controlled, open-label trial evaluating the efficacy and safety of chloroquine in the treatment of giardiasis in children. West Indian Med J 2010; 59:607-11.
25. Scragg JN, Powell SJ. Emetine hydrochloride and dehydroemetine combined with chloroquine in the treatment of children with amoebic liver abscess. Arch Dis Child 1968; 43:121-3.
26. Mita T, Tanabe K, Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int 2009; 58:201-9.
27. Mu J, Ferdig MT, Feng X, et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol 2003; 49:977-89.
28. Ord R, Alexander N, Dunyo S, et al. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect Dis 2007; 196:1613-9.
29. Ursing J, Kofoed PE, Rodrigues A, Rombo L. No seasonal accumulation of resistant P. Falciparum when high-dose chloroquine is used. PLoS One 2009; 4: e6866.
30. Chandra RS, Orazem J, Ubben D, Duparc S, Robbins J, Vandenbroucke P. Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa. Malaria J 2013; 12:122.